开云app官网登录入口网页版-官方正版

[GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2200145, encodeId=d4cb2200145cc, content=偏重的研究方向：分子生物学 经验分享：已接收，希望今年if保住9分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365b5687069, createdName=ms7000001898488025, createdTime=Wed Apr 24 16:09:07 CST 2024, time=2024-04-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2153492, encodeId=73392153492b6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：恶心人的期刊，第一次投2周左右说因为没有找到审稿人就给拒了。然后和编辑battle也没有回信就再投了，这次状态变了但是没给送审又给拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78186386984, createdName=ms2000000311873048, createdTime=Fri Aug 18 23:35:39 CST 2023, time=2023-08-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2223626, encodeId=512f2223626cd, content=偏重的研究方向：分子生物学;医学;凋亡 经验分享：2024-08-25 投稿，当天active 2024-08-30 replace消失，期待送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Mon Sep 02 07:52:07 CST 2024, time=2024-09-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1229470, encodeId=18a012294e0fa, content=请问状态一直是（active)Received 。。。This manuscript is under review. 有可能已经送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa435565605, createdName=ms5000000625918473, createdTime=Wed Jun 29 15:01:26 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973402, encodeId=e0d19e340260, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;基因功能 ;蛋白 经验分享：两年前中过一篇。这次再投一篇数据和质量差不多的，悲剧了。证明现在稿量很大，难投了，内卷了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3b151623119, createdName=echo1365, createdTime=Mon Jun 14 09:31:25 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205182, encodeId=a2961205182a4, content=Manuscript file和Cover letter文件后面的“replace”消失， Stats状态栏显示的是（active），然后显示的是Received 2022-3-9 from IP *.*.*.* This manuscript is under review. 请问这个状态代表的是已经送外审了吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59875648511, createdName=ms8000000802797021, createdTime=Wed Mar 23 11:04:10 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117981, encodeId=f6a1211e981d8, content=2.8号投稿，审稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Mon Mar 06 19:49:41 CST 2023, time=2023-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2139356, encodeId=cfd42139356ab, content=偏重的研究方向：肿瘤;基因功能 经验分享：这个期刊初次投稿后一直under review ，replace也还在，请问一般要多久编辑才会拒稿呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08728711142, createdName=ms2000001238004064, createdTime=Sat May 27 11:37:14 CST 2023, time=2023-05-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2107519, encodeId=e82a210e5198e, content=请问一下这个杂志投稿replace消失，显示状态为active，****is under review是送外审的意思吗？会不会编辑直接拒稿呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3fc55122990, createdName=cTuT, createdTime=Mon Dec 26 16:59:52 CST 2022, time=2022-12-26, status=1, ipAttribution=广东省)]

2022-02-23 悬崖听风007

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤免疫
经验分享：Received 2021-12-16 from IP
Minor revision 2022-2-8
Received 2022-2-17 from IP
Final accept 2022-2-22
Pre-publish-fee 2022-2-22
投稿到接受2个月零几天，效率杠杠的。感恩。

127 20

展开20条回复

[GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2200145, encodeId=d4cb2200145cc, content=偏重的研究方向：分子生物学 经验分享：已接收，希望今年if保住9分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365b5687069, createdName=ms7000001898488025, createdTime=Wed Apr 24 16:09:07 CST 2024, time=2024-04-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2153492, encodeId=73392153492b6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：恶心人的期刊，第一次投2周左右说因为没有找到审稿人就给拒了。然后和编辑battle也没有回信就再投了，这次状态变了但是没给送审又给拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78186386984, createdName=ms2000000311873048, createdTime=Fri Aug 18 23:35:39 CST 2023, time=2023-08-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2223626, encodeId=512f2223626cd, content=偏重的研究方向：分子生物学;医学;凋亡 经验分享：2024-08-25 投稿，当天active 2024-08-30 replace消失，期待送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Mon Sep 02 07:52:07 CST 2024, time=2024-09-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1229470, encodeId=18a012294e0fa, content=请问状态一直是（active)Received 。。。This manuscript is under review. 有可能已经送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa435565605, createdName=ms5000000625918473, createdTime=Wed Jun 29 15:01:26 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973402, encodeId=e0d19e340260, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;基因功能 ;蛋白 经验分享：两年前中过一篇。这次再投一篇数据和质量差不多的，悲剧了。证明现在稿量很大，难投了，内卷了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3b151623119, createdName=echo1365, createdTime=Mon Jun 14 09:31:25 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205182, encodeId=a2961205182a4, content=Manuscript file和Cover letter文件后面的“replace”消失， Stats状态栏显示的是（active），然后显示的是Received 2022-3-9 from IP *.*.*.* This manuscript is under review. 请问这个状态代表的是已经送外审了吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59875648511, createdName=ms8000000802797021, createdTime=Wed Mar 23 11:04:10 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117981, encodeId=f6a1211e981d8, content=2.8号投稿，审稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Mon Mar 06 19:49:41 CST 2023, time=2023-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2139356, encodeId=cfd42139356ab, content=偏重的研究方向：肿瘤;基因功能 经验分享：这个期刊初次投稿后一直under review ，replace也还在，请问一般要多久编辑才会拒稿呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08728711142, createdName=ms2000001238004064, createdTime=Sat May 27 11:37:14 CST 2023, time=2023-05-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2107519, encodeId=e82a210e5198e, content=请问一下这个杂志投稿replace消失，显示状态为active，****is under review是送外审的意思吗？会不会编辑直接拒稿呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3fc55122990, createdName=cTuT, createdTime=Mon Dec 26 16:59:52 CST 2022, time=2022-12-26, status=1, ipAttribution=广东省)]

2024-04-24 ms7000001898488025 来自北京

偏重的研究方向：分子生物学
经验分享：已接收，希望今年if保住9分

57 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2200145, encodeId=d4cb2200145cc, content=偏重的研究方向：分子生物学 经验分享：已接收，希望今年if保住9分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365b5687069, createdName=ms7000001898488025, createdTime=Wed Apr 24 16:09:07 CST 2024, time=2024-04-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2153492, encodeId=73392153492b6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：恶心人的期刊，第一次投2周左右说因为没有找到审稿人就给拒了。然后和编辑battle也没有回信就再投了，这次状态变了但是没给送审又给拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78186386984, createdName=ms2000000311873048, createdTime=Fri Aug 18 23:35:39 CST 2023, time=2023-08-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2223626, encodeId=512f2223626cd, content=偏重的研究方向：分子生物学;医学;凋亡 经验分享：2024-08-25 投稿，当天active 2024-08-30 replace消失，期待送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Mon Sep 02 07:52:07 CST 2024, time=2024-09-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1229470, encodeId=18a012294e0fa, content=请问状态一直是（active)Received 。。。This manuscript is under review. 有可能已经送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa435565605, createdName=ms5000000625918473, createdTime=Wed Jun 29 15:01:26 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973402, encodeId=e0d19e340260, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;基因功能 ;蛋白 经验分享：两年前中过一篇。这次再投一篇数据和质量差不多的，悲剧了。证明现在稿量很大，难投了，内卷了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3b151623119, createdName=echo1365, createdTime=Mon Jun 14 09:31:25 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205182, encodeId=a2961205182a4, content=Manuscript file和Cover letter文件后面的“replace”消失， Stats状态栏显示的是（active），然后显示的是Received 2022-3-9 from IP *.*.*.* This manuscript is under review. 请问这个状态代表的是已经送外审了吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59875648511, createdName=ms8000000802797021, createdTime=Wed Mar 23 11:04:10 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117981, encodeId=f6a1211e981d8, content=2.8号投稿，审稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Mon Mar 06 19:49:41 CST 2023, time=2023-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2139356, encodeId=cfd42139356ab, content=偏重的研究方向：肿瘤;基因功能 经验分享：这个期刊初次投稿后一直under review ，replace也还在，请问一般要多久编辑才会拒稿呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08728711142, createdName=ms2000001238004064, createdTime=Sat May 27 11:37:14 CST 2023, time=2023-05-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2107519, encodeId=e82a210e5198e, content=请问一下这个杂志投稿replace消失，显示状态为active，****is under review是送外审的意思吗？会不会编辑直接拒稿呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3fc55122990, createdName=cTuT, createdTime=Mon Dec 26 16:59:52 CST 2022, time=2022-12-26, status=1, ipAttribution=广东省)]

2023-08-18 ms2000000311873048 来自湖南省

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：恶心人的期刊，第一次投2周左右说因为没有找到审稿人就给拒了。然后和编辑battle也没有回信就再投了，这次状态变了但是没给送审又给拒了。

59 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2200145, encodeId=d4cb2200145cc, content=偏重的研究方向：分子生物学 经验分享：已接收，希望今年if保住9分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365b5687069, createdName=ms7000001898488025, createdTime=Wed Apr 24 16:09:07 CST 2024, time=2024-04-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2153492, encodeId=73392153492b6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：恶心人的期刊，第一次投2周左右说因为没有找到审稿人就给拒了。然后和编辑battle也没有回信就再投了，这次状态变了但是没给送审又给拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78186386984, createdName=ms2000000311873048, createdTime=Fri Aug 18 23:35:39 CST 2023, time=2023-08-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2223626, encodeId=512f2223626cd, content=偏重的研究方向：分子生物学;医学;凋亡 经验分享：2024-08-25 投稿，当天active 2024-08-30 replace消失，期待送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Mon Sep 02 07:52:07 CST 2024, time=2024-09-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1229470, encodeId=18a012294e0fa, content=请问状态一直是（active)Received 。。。This manuscript is under review. 有可能已经送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa435565605, createdName=ms5000000625918473, createdTime=Wed Jun 29 15:01:26 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973402, encodeId=e0d19e340260, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;基因功能 ;蛋白 经验分享：两年前中过一篇。这次再投一篇数据和质量差不多的，悲剧了。证明现在稿量很大，难投了，内卷了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3b151623119, createdName=echo1365, createdTime=Mon Jun 14 09:31:25 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205182, encodeId=a2961205182a4, content=Manuscript file和Cover letter文件后面的“replace”消失， Stats状态栏显示的是（active），然后显示的是Received 2022-3-9 from IP *.*.*.* This manuscript is under review. 请问这个状态代表的是已经送外审了吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59875648511, createdName=ms8000000802797021, createdTime=Wed Mar 23 11:04:10 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117981, encodeId=f6a1211e981d8, content=2.8号投稿，审稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Mon Mar 06 19:49:41 CST 2023, time=2023-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2139356, encodeId=cfd42139356ab, content=偏重的研究方向：肿瘤;基因功能 经验分享：这个期刊初次投稿后一直under review ，replace也还在，请问一般要多久编辑才会拒稿呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08728711142, createdName=ms2000001238004064, createdTime=Sat May 27 11:37:14 CST 2023, time=2023-05-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2107519, encodeId=e82a210e5198e, content=请问一下这个杂志投稿replace消失，显示状态为active，****is under review是送外审的意思吗？会不会编辑直接拒稿呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3fc55122990, createdName=cTuT, createdTime=Mon Dec 26 16:59:52 CST 2022, time=2022-12-26, status=1, ipAttribution=广东省)]

2024-09-02 1891e859aem 来自广东省

偏重的研究方向：分子生物学;医学;凋亡
经验分享：2024-08-25 投稿，当天active 2024-08-30 replace消失，期待送审

12 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2200145, encodeId=d4cb2200145cc, content=偏重的研究方向：分子生物学 经验分享：已接收，希望今年if保住9分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365b5687069, createdName=ms7000001898488025, createdTime=Wed Apr 24 16:09:07 CST 2024, time=2024-04-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2153492, encodeId=73392153492b6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：恶心人的期刊，第一次投2周左右说因为没有找到审稿人就给拒了。然后和编辑battle也没有回信就再投了，这次状态变了但是没给送审又给拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78186386984, createdName=ms2000000311873048, createdTime=Fri Aug 18 23:35:39 CST 2023, time=2023-08-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2223626, encodeId=512f2223626cd, content=偏重的研究方向：分子生物学;医学;凋亡 经验分享：2024-08-25 投稿，当天active 2024-08-30 replace消失，期待送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Mon Sep 02 07:52:07 CST 2024, time=2024-09-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1229470, encodeId=18a012294e0fa, content=请问状态一直是（active)Received 。。。This manuscript is under review. 有可能已经送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa435565605, createdName=ms5000000625918473, createdTime=Wed Jun 29 15:01:26 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973402, encodeId=e0d19e340260, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;基因功能 ;蛋白 经验分享：两年前中过一篇。这次再投一篇数据和质量差不多的，悲剧了。证明现在稿量很大，难投了，内卷了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3b151623119, createdName=echo1365, createdTime=Mon Jun 14 09:31:25 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205182, encodeId=a2961205182a4, content=Manuscript file和Cover letter文件后面的“replace”消失， Stats状态栏显示的是（active），然后显示的是Received 2022-3-9 from IP *.*.*.* This manuscript is under review. 请问这个状态代表的是已经送外审了吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59875648511, createdName=ms8000000802797021, createdTime=Wed Mar 23 11:04:10 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117981, encodeId=f6a1211e981d8, content=2.8号投稿，审稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Mon Mar 06 19:49:41 CST 2023, time=2023-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2139356, encodeId=cfd42139356ab, content=偏重的研究方向：肿瘤;基因功能 经验分享：这个期刊初次投稿后一直under review ，replace也还在，请问一般要多久编辑才会拒稿呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08728711142, createdName=ms2000001238004064, createdTime=Sat May 27 11:37:14 CST 2023, time=2023-05-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2107519, encodeId=e82a210e5198e, content=请问一下这个杂志投稿replace消失，显示状态为active，****is under review是送外审的意思吗？会不会编辑直接拒稿呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3fc55122990, createdName=cTuT, createdTime=Mon Dec 26 16:59:52 CST 2022, time=2022-12-26, status=1, ipAttribution=广东省)]

2022-06-29 ms5000000625918473

请问状态一直是（active)Received 。。。This manuscript is under review.
有可能已经送审了吗？

111 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2200145, encodeId=d4cb2200145cc, content=偏重的研究方向：分子生物学 经验分享：已接收，希望今年if保住9分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365b5687069, createdName=ms7000001898488025, createdTime=Wed Apr 24 16:09:07 CST 2024, time=2024-04-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2153492, encodeId=73392153492b6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：恶心人的期刊，第一次投2周左右说因为没有找到审稿人就给拒了。然后和编辑battle也没有回信就再投了，这次状态变了但是没给送审又给拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78186386984, createdName=ms2000000311873048, createdTime=Fri Aug 18 23:35:39 CST 2023, time=2023-08-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2223626, encodeId=512f2223626cd, content=偏重的研究方向：分子生物学;医学;凋亡 经验分享：2024-08-25 投稿，当天active 2024-08-30 replace消失，期待送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Mon Sep 02 07:52:07 CST 2024, time=2024-09-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1229470, encodeId=18a012294e0fa, content=请问状态一直是（active)Received 。。。This manuscript is under review. 有可能已经送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa435565605, createdName=ms5000000625918473, createdTime=Wed Jun 29 15:01:26 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973402, encodeId=e0d19e340260, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;基因功能 ;蛋白 经验分享：两年前中过一篇。这次再投一篇数据和质量差不多的，悲剧了。证明现在稿量很大，难投了，内卷了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3b151623119, createdName=echo1365, createdTime=Mon Jun 14 09:31:25 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205182, encodeId=a2961205182a4, content=Manuscript file和Cover letter文件后面的“replace”消失， Stats状态栏显示的是（active），然后显示的是Received 2022-3-9 from IP *.*.*.* This manuscript is under review. 请问这个状态代表的是已经送外审了吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59875648511, createdName=ms8000000802797021, createdTime=Wed Mar 23 11:04:10 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117981, encodeId=f6a1211e981d8, content=2.8号投稿，审稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Mon Mar 06 19:49:41 CST 2023, time=2023-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2139356, encodeId=cfd42139356ab, content=偏重的研究方向：肿瘤;基因功能 经验分享：这个期刊初次投稿后一直under review ，replace也还在，请问一般要多久编辑才会拒稿呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08728711142, createdName=ms2000001238004064, createdTime=Sat May 27 11:37:14 CST 2023, time=2023-05-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2107519, encodeId=e82a210e5198e, content=请问一下这个杂志投稿replace消失，显示状态为active，****is under review是送外审的意思吗？会不会编辑直接拒稿呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3fc55122990, createdName=cTuT, createdTime=Mon Dec 26 16:59:52 CST 2022, time=2022-12-26, status=1, ipAttribution=广东省)]

2021-06-14 echo1365

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：肿瘤;基因功能 ;蛋白
经验分享：两年前中过一篇。这次再投一篇数据和质量差不多的，悲剧了。证明现在稿量很大，难投了，内卷了

79 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2200145, encodeId=d4cb2200145cc, content=偏重的研究方向：分子生物学 经验分享：已接收，希望今年if保住9分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365b5687069, createdName=ms7000001898488025, createdTime=Wed Apr 24 16:09:07 CST 2024, time=2024-04-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2153492, encodeId=73392153492b6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：恶心人的期刊，第一次投2周左右说因为没有找到审稿人就给拒了。然后和编辑battle也没有回信就再投了，这次状态变了但是没给送审又给拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78186386984, createdName=ms2000000311873048, createdTime=Fri Aug 18 23:35:39 CST 2023, time=2023-08-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2223626, encodeId=512f2223626cd, content=偏重的研究方向：分子生物学;医学;凋亡 经验分享：2024-08-25 投稿，当天active 2024-08-30 replace消失，期待送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Mon Sep 02 07:52:07 CST 2024, time=2024-09-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1229470, encodeId=18a012294e0fa, content=请问状态一直是（active)Received 。。。This manuscript is under review. 有可能已经送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa435565605, createdName=ms5000000625918473, createdTime=Wed Jun 29 15:01:26 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973402, encodeId=e0d19e340260, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;基因功能 ;蛋白 经验分享：两年前中过一篇。这次再投一篇数据和质量差不多的，悲剧了。证明现在稿量很大，难投了，内卷了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3b151623119, createdName=echo1365, createdTime=Mon Jun 14 09:31:25 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205182, encodeId=a2961205182a4, content=Manuscript file和Cover letter文件后面的“replace”消失， Stats状态栏显示的是（active），然后显示的是Received 2022-3-9 from IP *.*.*.* This manuscript is under review. 请问这个状态代表的是已经送外审了吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59875648511, createdName=ms8000000802797021, createdTime=Wed Mar 23 11:04:10 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117981, encodeId=f6a1211e981d8, content=2.8号投稿，审稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Mon Mar 06 19:49:41 CST 2023, time=2023-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2139356, encodeId=cfd42139356ab, content=偏重的研究方向：肿瘤;基因功能 经验分享：这个期刊初次投稿后一直under review ，replace也还在，请问一般要多久编辑才会拒稿呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08728711142, createdName=ms2000001238004064, createdTime=Sat May 27 11:37:14 CST 2023, time=2023-05-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2107519, encodeId=e82a210e5198e, content=请问一下这个杂志投稿replace消失，显示状态为active，****is under review是送外审的意思吗？会不会编辑直接拒稿呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3fc55122990, createdName=cTuT, createdTime=Mon Dec 26 16:59:52 CST 2022, time=2022-12-26, status=1, ipAttribution=广东省)]

2022-03-23 ms8000000802797021

Manuscript file和Cover letter文件后面的“replace”消失，
Stats状态栏显示的是（active），然后显示的是Received 2022-3-9 from IP *.*.*.* This manuscript is under review.

请问这个状态代表的是已经送外审了吗？

98 14

展开14条回复

[GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2200145, encodeId=d4cb2200145cc, content=偏重的研究方向：分子生物学 经验分享：已接收，希望今年if保住9分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365b5687069, createdName=ms7000001898488025, createdTime=Wed Apr 24 16:09:07 CST 2024, time=2024-04-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2153492, encodeId=73392153492b6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：恶心人的期刊，第一次投2周左右说因为没有找到审稿人就给拒了。然后和编辑battle也没有回信就再投了，这次状态变了但是没给送审又给拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78186386984, createdName=ms2000000311873048, createdTime=Fri Aug 18 23:35:39 CST 2023, time=2023-08-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2223626, encodeId=512f2223626cd, content=偏重的研究方向：分子生物学;医学;凋亡 经验分享：2024-08-25 投稿，当天active 2024-08-30 replace消失，期待送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Mon Sep 02 07:52:07 CST 2024, time=2024-09-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1229470, encodeId=18a012294e0fa, content=请问状态一直是（active)Received 。。。This manuscript is under review. 有可能已经送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa435565605, createdName=ms5000000625918473, createdTime=Wed Jun 29 15:01:26 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973402, encodeId=e0d19e340260, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;基因功能 ;蛋白 经验分享：两年前中过一篇。这次再投一篇数据和质量差不多的，悲剧了。证明现在稿量很大，难投了，内卷了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3b151623119, createdName=echo1365, createdTime=Mon Jun 14 09:31:25 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205182, encodeId=a2961205182a4, content=Manuscript file和Cover letter文件后面的“replace”消失， Stats状态栏显示的是（active），然后显示的是Received 2022-3-9 from IP *.*.*.* This manuscript is under review. 请问这个状态代表的是已经送外审了吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59875648511, createdName=ms8000000802797021, createdTime=Wed Mar 23 11:04:10 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117981, encodeId=f6a1211e981d8, content=2.8号投稿，审稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Mon Mar 06 19:49:41 CST 2023, time=2023-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2139356, encodeId=cfd42139356ab, content=偏重的研究方向：肿瘤;基因功能 经验分享：这个期刊初次投稿后一直under review ，replace也还在，请问一般要多久编辑才会拒稿呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08728711142, createdName=ms2000001238004064, createdTime=Sat May 27 11:37:14 CST 2023, time=2023-05-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2107519, encodeId=e82a210e5198e, content=请问一下这个杂志投稿replace消失，显示状态为active，****is under review是送外审的意思吗？会不会编辑直接拒稿呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3fc55122990, createdName=cTuT, createdTime=Mon Dec 26 16:59:52 CST 2022, time=2022-12-26, status=1, ipAttribution=广东省)]

2023-03-06 541350208 来自重庆

2.8号投稿，审稿中

74 20

展开20条回复

[GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2200145, encodeId=d4cb2200145cc, content=偏重的研究方向：分子生物学 经验分享：已接收，希望今年if保住9分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365b5687069, createdName=ms7000001898488025, createdTime=Wed Apr 24 16:09:07 CST 2024, time=2024-04-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2153492, encodeId=73392153492b6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：恶心人的期刊，第一次投2周左右说因为没有找到审稿人就给拒了。然后和编辑battle也没有回信就再投了，这次状态变了但是没给送审又给拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78186386984, createdName=ms2000000311873048, createdTime=Fri Aug 18 23:35:39 CST 2023, time=2023-08-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2223626, encodeId=512f2223626cd, content=偏重的研究方向：分子生物学;医学;凋亡 经验分享：2024-08-25 投稿，当天active 2024-08-30 replace消失，期待送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Mon Sep 02 07:52:07 CST 2024, time=2024-09-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1229470, encodeId=18a012294e0fa, content=请问状态一直是（active)Received 。。。This manuscript is under review. 有可能已经送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa435565605, createdName=ms5000000625918473, createdTime=Wed Jun 29 15:01:26 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973402, encodeId=e0d19e340260, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;基因功能 ;蛋白 经验分享：两年前中过一篇。这次再投一篇数据和质量差不多的，悲剧了。证明现在稿量很大，难投了，内卷了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3b151623119, createdName=echo1365, createdTime=Mon Jun 14 09:31:25 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205182, encodeId=a2961205182a4, content=Manuscript file和Cover letter文件后面的“replace”消失， Stats状态栏显示的是（active），然后显示的是Received 2022-3-9 from IP *.*.*.* This manuscript is under review. 请问这个状态代表的是已经送外审了吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59875648511, createdName=ms8000000802797021, createdTime=Wed Mar 23 11:04:10 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117981, encodeId=f6a1211e981d8, content=2.8号投稿，审稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Mon Mar 06 19:49:41 CST 2023, time=2023-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2139356, encodeId=cfd42139356ab, content=偏重的研究方向：肿瘤;基因功能 经验分享：这个期刊初次投稿后一直under review ，replace也还在，请问一般要多久编辑才会拒稿呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08728711142, createdName=ms2000001238004064, createdTime=Sat May 27 11:37:14 CST 2023, time=2023-05-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2107519, encodeId=e82a210e5198e, content=请问一下这个杂志投稿replace消失，显示状态为active，****is under review是送外审的意思吗？会不会编辑直接拒稿呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3fc55122990, createdName=cTuT, createdTime=Mon Dec 26 16:59:52 CST 2022, time=2022-12-26, status=1, ipAttribution=广东省)]

2023-05-27 ms2000001238004064 来自广东省

偏重的研究方向：肿瘤;基因功能
经验分享：这个期刊初次投稿后一直under review ，replace也还在，请问一般要多久编辑才会拒稿呢？

112 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2200145, encodeId=d4cb2200145cc, content=偏重的研究方向：分子生物学 经验分享：已接收，希望今年if保住9分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365b5687069, createdName=ms7000001898488025, createdTime=Wed Apr 24 16:09:07 CST 2024, time=2024-04-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2153492, encodeId=73392153492b6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：恶心人的期刊，第一次投2周左右说因为没有找到审稿人就给拒了。然后和编辑battle也没有回信就再投了，这次状态变了但是没给送审又给拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78186386984, createdName=ms2000000311873048, createdTime=Fri Aug 18 23:35:39 CST 2023, time=2023-08-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2223626, encodeId=512f2223626cd, content=偏重的研究方向：分子生物学;医学;凋亡 经验分享：2024-08-25 投稿，当天active 2024-08-30 replace消失，期待送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Mon Sep 02 07:52:07 CST 2024, time=2024-09-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1229470, encodeId=18a012294e0fa, content=请问状态一直是（active)Received 。。。This manuscript is under review. 有可能已经送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa435565605, createdName=ms5000000625918473, createdTime=Wed Jun 29 15:01:26 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973402, encodeId=e0d19e340260, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;基因功能 ;蛋白 经验分享：两年前中过一篇。这次再投一篇数据和质量差不多的，悲剧了。证明现在稿量很大，难投了，内卷了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3b151623119, createdName=echo1365, createdTime=Mon Jun 14 09:31:25 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205182, encodeId=a2961205182a4, content=Manuscript file和Cover letter文件后面的“replace”消失， Stats状态栏显示的是（active），然后显示的是Received 2022-3-9 from IP *.*.*.* This manuscript is under review. 请问这个状态代表的是已经送外审了吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59875648511, createdName=ms8000000802797021, createdTime=Wed Mar 23 11:04:10 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117981, encodeId=f6a1211e981d8, content=2.8号投稿，审稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Mon Mar 06 19:49:41 CST 2023, time=2023-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2139356, encodeId=cfd42139356ab, content=偏重的研究方向：肿瘤;基因功能 经验分享：这个期刊初次投稿后一直under review ，replace也还在，请问一般要多久编辑才会拒稿呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08728711142, createdName=ms2000001238004064, createdTime=Sat May 27 11:37:14 CST 2023, time=2023-05-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2107519, encodeId=e82a210e5198e, content=请问一下这个杂志投稿replace消失，显示状态为active，****is under review是送外审的意思吗？会不会编辑直接拒稿呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3fc55122990, createdName=cTuT, createdTime=Mon Dec 26 16:59:52 CST 2022, time=2022-12-26, status=1, ipAttribution=广东省)]

2022-12-26 cTuT 来自广东省

请问一下这个杂志投稿replace消失，显示状态为active，****is under review是送外审的意思吗？会不会编辑直接拒稿呢？

89 4

展开4条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务